article thumbnail

Time to change the channel? The future for customer engagement models

pharmaphorum

The pandemic has triggered a change in how pharmaceutical companies are engaging with healthcare professionals. When IQVIA polled non COVID-19 treating Italian HCPs in March when the crisis was at its worst, it asked HCPs if they still welcomed pharmaceutical company engagement during the crisis. The answer was yes.

article thumbnail

Enabling the leaders of the future

pharmaphorum

From clear communication with an unsettled, dispersed workforce to maintaining positive energy and managing people’s working hours, the need for open, inclusive and empathetic leadership has never been more important. . COVID-19 has amplified what is expected of leaders in workplaces around the world. About the author.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The 20 Key Moments in the 340B Program's 30-Year History

Omnicell

There was bipartisan support for the program at the hearing and support for measures such as requiring pharmaceutical companies to publish their prices in a password protected site on HRSA's website. Four of the five staffers originally involved in the investigation now work for or lobby for the pharmaceutical industry.

article thumbnail

What can pharma marketing learn from other regulated industries?

pharmaphorum

“A lot of printed materials have been migrated to digital so that patients can opt-in to receive digital communications or HCPs can receive digital product or disease state information in the form of rep-triggered emails and microsites. Joanna Carlish. The idea is about really tapping into where the customer is in their journey.

article thumbnail

Risk sharing agreements soar as market access risk increases

Pharmaceutical Technology

GlobalData calculates these risk scores by evaluating several qualitative and quantitative factors to establish the quality of conditions and the level of stability of the market access environment encountered by pharmaceutical companies in each country. These can include compulsory discounts, manufacturing discounts and more.

article thumbnail

Cerba Research and Teddy Lab sign Memorandum of Understanding on entering into a discussion for Joint Venture

Pharmaceutical Technology

The two companies, along with Cerba Research’s specialty virology subsidiary Viroclinics-DDL, have had a long track record in collaborative projects since 2012, from specialty assay transfers to full clinical trial management and logistics support services. SZ) and Tigermed (300347.SZ

article thumbnail

The impact of clinical trial decentralisation on the pharma supply chain

Pharmaceutical Technology

7,000 more clinical trials take place each year in the Asia-Pacific region compared with 2012, and 1,200 more in the Middle East and Africa. Shoring these up will be a prerequisite for ushering in the age of decentralised pharmaceuticals. The world of clinical trials is changing. Please check your email to download the Report.